---
title: "辉瑞指控诺和诺德涉嫌策划规避反垄断审查，并通过破坏辉瑞与 Metsera 的交易来 “扼杀一家新兴竞争对手”。"
description: "辉瑞指控诺和诺德涉嫌策划规避反垄断审查，并通过破坏辉瑞与 Metsera 的交易来 “扼杀一家新兴竞争对手”。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/263812248.md"
published_at: "2025-10-31T21:54:00.000Z"
---

# 辉瑞指控诺和诺德涉嫌策划规避反垄断审查，并通过破坏辉瑞与 Metsera 的交易来 “扼杀一家新兴竞争对手”。

辉瑞指控诺和诺德涉嫌策划规避反垄断审查，并通过破坏辉瑞与 Metsera 的交易来 “扼杀一家新兴竞争对手”。

### Related Stocks

- [NVO.US - 诺和诺德公司](https://longbridge.com/zh-CN/quote/NVO.US.md)
- [PFE.US - 辉瑞](https://longbridge.com/zh-CN/quote/PFE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Novo Nordisk A/S - share repurchase programme | Novo Nordisk A/S has initiated a share repurchase programme of up to DKK 15 billion, starting from 4 February 2026. As o | [Link](https://longbridge.com/zh-CN/news/276056741.md) |
| GLP-1 Anti-Obesity U.S. Drug Market In Four Charts | UBS analysts, led by Matthew Weston, have analyzed trends in the U.S. GLP-1 anti-obesity drug market, focusing on new-to | [Link](https://longbridge.com/zh-CN/news/276280378.md) |
| Pfizer Targets Real-World Myeloma Data in Taiwan With New Elranatamab Study | Pfizer Inc. (PFE) is launching a new observational study in Taiwan to evaluate the effectiveness of its multiple myeloma | [Link](https://longbridge.com/zh-CN/news/276252273.md) |
| Novo Nordisk: Will Have Replacements for Ozempic and Wegovy Ready When Patents Expire - Berlingske | Danish pharmaceutical company Novo Nordisk plans to have replacement drugs ready for Ozempic and Wegovy when their paten | [Link](https://longbridge.com/zh-CN/news/276314777.md) |
| Berenberg Bank Reaffirms Their Buy Rating on Novo Nordisk (0QIU) | Berenberg Bank analyst Kerry Holford has reaffirmed a Buy rating on Novo Nordisk (0QIU) with a price target of DKK360.00 | [Link](https://longbridge.com/zh-CN/news/275719942.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。